{"title":"向肿瘤输送纳米粒子：从 EPR 和 ATR 机制到临床影响","authors":"Anshuman Dasgupta, Alexandros Marios Sofias, Fabian Kiessling, Twan Lammers","doi":"10.1038/s44222-024-00203-3","DOIUrl":null,"url":null,"abstract":"New insights into active versus passive nanoparticle tumour entry and exit mechanisms are enriching the understanding of tumour-targeted drug delivery. Here we align the principles of enhanced permeability and retention (EPR) and active transport and retention (ATR), and outline how their mechanistic features can be employed to improve the performance and clinical impact of cancer nanomedicines.","PeriodicalId":74248,"journal":{"name":"Nature reviews bioengineering","volume":"2 9","pages":"714-716"},"PeriodicalIF":37.6000,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nanoparticle delivery to tumours: from EPR and ATR mechanisms to clinical impact\",\"authors\":\"Anshuman Dasgupta, Alexandros Marios Sofias, Fabian Kiessling, Twan Lammers\",\"doi\":\"10.1038/s44222-024-00203-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"New insights into active versus passive nanoparticle tumour entry and exit mechanisms are enriching the understanding of tumour-targeted drug delivery. Here we align the principles of enhanced permeability and retention (EPR) and active transport and retention (ATR), and outline how their mechanistic features can be employed to improve the performance and clinical impact of cancer nanomedicines.\",\"PeriodicalId\":74248,\"journal\":{\"name\":\"Nature reviews bioengineering\",\"volume\":\"2 9\",\"pages\":\"714-716\"},\"PeriodicalIF\":37.6000,\"publicationDate\":\"2024-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature reviews bioengineering\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.nature.com/articles/s44222-024-00203-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature reviews bioengineering","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s44222-024-00203-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Nanoparticle delivery to tumours: from EPR and ATR mechanisms to clinical impact
New insights into active versus passive nanoparticle tumour entry and exit mechanisms are enriching the understanding of tumour-targeted drug delivery. Here we align the principles of enhanced permeability and retention (EPR) and active transport and retention (ATR), and outline how their mechanistic features can be employed to improve the performance and clinical impact of cancer nanomedicines.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
